Skip to main content
. 2019 May 16;3(7):1423–1444. doi: 10.1210/js.2019-00004

Figure 3.

Figure 3.

Food intake suppression by OXT analogs is modulated by their pharmacokinetic properties and receptor selectivity. (A) A single injection (IP) of OXT dose-dependently suppressed food intake in lean male C57BL/6 mice (n = 7 per group) for up to 3 h. (B) A single injection (IP) of acylated-OXT dose-dependently suppressed food intake in lean male C57BL/6 mice (n = 7 per group) for up to 36 h. (C) Various doses of OXTGly (IP) did not cause reduction in food intake in lean male C57BL/6 mice (n = 7 per group). (D) Twenty-four hour food intake measurement after a single injection (IP) of OXT (2 mg/kg) or OXTGly (2 mg/kg) in lean male C57BL/6 mice (n = 7 per group). (E) Various doses of acylated-OXTGly (IP) did not cause food intake reduction in lean male C57BL/6 mice (n = 7 per group). (F) Food intake after coinjections (IP) of conivaptan (0.5 mg/kg) and OXT (2 mg/kg) in lean male C57BL/6 mice (n = 6 per group). For OXT, 1 mg/kg = 0.99 μmol/kg; for OXTGly, 1 mg/kg = 1.05 μmol/kg; for acylated-OXT, 1 mg/kg = 0.54 μmol/kg; for acylated-OXTGly, 1 mg/kg = 0.55 μmol/kg. *P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA followed by a Tukey multiple comparisons test.